Sirera Guillem, Videla Sebastià, López-Blázquez Raquel, Llatjos Mariona, Tarrats Antoni, Castellà Eva, Grane Nuria, Alcalde Carmen, Tural Cristina, Rey-Joly Celestino, Clotet Bonaventura
Department of Medicine, University Hospital Germans Trias i Pujol, Badalona (Barcelona )08916, Spain.
AIDS Res Hum Retroviruses. 2007 Aug;23(8):965-71. doi: 10.1089/aid.2006.0293.
The influence of HAART on the evolution to cervical squamous intraepithelial lesions (SIL) among HIV(+) women with a normal cytological test in the HAART era was studied. A retrospective cohort study (1997-2005) of HIV-infected women treated with HAART was conducted. Those with a normal cervical cytology (Papanicolaou test) and at least one subsequent test were included. Survival (time until diagnosis of SIL), univariate, and multivariate analyses were performed. A total of 133 HIV-infected patients treated with HAART were included. The incidence of SIL was 35% (47 patients). SIL was diagnosed in 36 of 110 (33%) patients with a baseline and final immunological status of >200 CD4 cells/microl and in 6 of 9 (67%) patients with a baseline and final immunological status of < or =200 CD4 (OR: 0.24, 95% CI: 0.06-1.03, p = 0.041). SIL was diagnosed in 10 of 60 (17%) patients with an undetectable baseline and final HIV viral load and in 36 of 70 (51%) patients with a detectable HIV viral load (OR: 0.19, 95% CI: 0.07-0.46, p < 0.001). A high incidence of SIL (cancer precursor lesions) was observed among HIV(+) women without a background of cervical pathology. The effect of HAART on the control of HIV replication and of immunological status (>200 CD4) through the follow-up was associated with a reduction of SIL.
本研究探讨了高效抗逆转录病毒治疗(HAART)时代,在细胞学检查正常的HIV阳性女性中,HAART对宫颈鳞状上皮内病变(SIL)进展的影响。对1997年至2005年接受HAART治疗的HIV感染女性进行了一项回顾性队列研究。纳入宫颈细胞学检查(巴氏试验)正常且至少有一次后续检查的女性。进行了生存分析(直至诊断为SIL的时间)、单因素分析和多因素分析。共纳入133例接受HAART治疗的HIV感染患者。SIL的发生率为35%(47例患者)。在110例基线和最终免疫状态>200个CD4细胞/微升的患者中,有36例(33%)诊断为SIL;在9例基线和最终免疫状态≤200个CD4细胞/微升的患者中,有6例(67%)诊断为SIL(比值比:0.24,95%置信区间:0.06 - 1.03,p = 0.041)。在60例基线和最终HIV病毒载量不可检测的患者中,有10例(17%)诊断为SIL;在70例HIV病毒载量可检测的患者中,有36例(51%)诊断为SIL(比值比:0.19,95%置信区间:0.07 - 0.46,p < 0.001)。在无宫颈病变背景的HIV阳性女性中观察到SIL(癌症前驱病变)的高发生率。通过随访,HAART对HIV复制的控制作用以及免疫状态(>200个CD4细胞)与SIL的减少相关。